newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports First Quarter 2025 Financial Results

– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company